

optimal utilization of surface run-off water and ground water recharging, boring of new tube wells, covering of nallah etc. The project is expected to cost Rs. 1300 crores and its planned to be implemented phase-wise as a part of vision 2025. The project has not been considered by the Government yet. Its implementation will depend on due clearances and availability of funds.

TB and Hepatitis patients

488. SHRITARINI KANTA ROY: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state the total number of TB and Hepatitis patients reported in 1999, 2000 and 2001, State-wise?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRI A RAJA): A Statement indicating the State-wise details of TB and Hepatitis patients during 1999, 2000 and 2001 is given at Statement I and Statement II respectively.

Statement-I

State-wise number of sputum positive TB cases detected and put on treatment during 1999-2000 to 2002 under the National TB Control Programme

Sl. No.	Name of the State/ Union Territory	1999-2000	2000-2001	2001-2002
1.	Andhra Pradesh			
2.	Arunachal Pradesh	414	410	446
3.	Assam	209	2059	3037
4.	Bihar	6980	8325	11532
5.	Chhattisgarh	-	-	3213
6.	Goa	515	561	495
7.	Gujarat	34911	30981	32212
8.	Haryana	9226	8444	10942
9.	Himachal Pradesh	512	924	1132
10.	Jammu & Kashmir	533	830	4862
11.	Jharkhand		-	878

[22 July, 2002]

RAJYA SABHA

Sl. No.	Name of the State/ Union Territory	1999-2000	2000-2001	2001-2002
12.	Karnataka	20244	26133	31099
13.	Kerala	1534	2314	4473
14.	Madhya Pradesh	23683	25037	28942
15.	Maharashtra	64966	63797	53410
16.	Manipur	1012	1385	1473
17.	Meghalaya	508	665	915
18.	Mizoram	299	336	369
19.	Nagaland	643	314	571
20.	Orissa	12106	4480	6004
21.	Punjab	9783	10670	9336
22.	Rajasthan	22953	23584	33814
23.	Sikkim	417	489	589
24.	Tamil Nadu	25756	24533	22502
25.	Tripura	981	5555	928
26.	Uttaranchal	-	-	3909
27.	Uttar Pradesh	65596	62802	80666
28.	West Bengal	15595	3721	3688
29.	A&N Islands	210	265	209
30.	Chandigarh	23	35	0
31.	D&N Haveli	187	182	113
32.	Daman & Diu	153	170	101
33.	Delhi	26911	17518	18521
34.	Lakshadweep	0	5	1
35.	Pondicherry	1303	1436	1511
Total		373055	356522	402743

Statement-II*State-wise number of Hepatitis patients during 1999 to 2001*

Sl. No.	Name of the State/UT	1999	2000	2001
1.	Andhra Pradesh	36925	27595	24530
2.	Arunachal Pradesh	-	-	-
3.	Assam	-	-	-
4.	Bihar	-	-	-
5.	Chhattisgarh	-	-	-
6.	Goa	151	229	124
7.	Gujarat	2676*	3714	2561
8.	Haryana	1733	1086	2731
9.	Himachal Pradesh	1843	1464	1275
10.	Jammu & Kashmir	6956	6171	4226
11.	Jharkhand	-	-	-
12.	Karnataka	9150	24571	6444
13.	Kerala	7197	5521	3997
14.	Madhya Pradesh	3928**	6620	2983
15.	Maharashtra	29221	40962	39911
16.	Manipur	690	728	1558
17.	Meghalaya	374	239	500
18.	Mizoram	598	943	1183
19.	Nagaland	36	408	-
20.	Orissa	10338	14020	7334
21.	Punjab	2347	1796	2634
22.	Rajasthan	2559	1801	2955
23.	Sikkim	511	594	409
24.	Tamil Nadu	2109	1740	1632
25.	Tripura	122	113	1784
26.	Uttaranchal	-	-	-
27.	Uttar Pradesh	2120	988	1885
28.	West Bengal	5867	5831	6303

SI. No.	Name of the State/UT	1999	2000	2001
29.	A&N Islands	247	252	536
30.	Chandigarh	234	219	282
31.	D&N Haveli	03***	-	-
32.	Daman & Diu	37	41	-
33.	Delhi	2929	4077	3159
34.	Lakshadweep	319	258	71
35.	Pondicherry	578	932	611
TOTAL (ALL INDIA)		131798	152713	121618

Data is provisional

* Report for the month of March to June not received.

** Report for the months of February, August to December, 1999 not received.

*** Only for January, 1999.

High-tech drug for Diabetes

489. SHRIYADLAPATIVENKAT RAO: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether Government are aware that a new high-tech drug is proving effective for all types of diabetes and is reducing dependence on insulin shots in the USA;

(b) if so, whether Government are taking steps to make this drug available in the country; and

(c) the other details in this regard?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRI A. RAJA): (a) to (c) According to Indian Council of Medical Research (ICMR), Thiazolidinedione derivatives with insulin sensitizing activity such as troglitazone, rosiglitazone and pioglitazone lower the blood levels of glucose, free fatty acids and triglycerides and appear to reduce insulin resistance, possibly by increasing the activity of insulin receptor kinase. These drugs have been approved for use in obese